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Retrospective chart review of catatonia in
child and adolescent psychiatric patients
Introduction
Catatonia is a syndrome characterized by motor
abnormalities that include excessive movements
(constant or periodic over-activity ⁄ excitement,
unprovoked aggression or auto-aggression),
reduced mobility (progressive slowness that may
interfere with functioning, cessation of all move-
ments in some cases), abnormal movements (repet-
itive stereotyped movements, mimicking the
movements of others, grimacing, mannerisms, pos-
turing, freezing), reduced or other abnormalities of
Significant outcomes
• Catatonia is frequently missed among children and adolescents receiving psychiatric treatment. This
appears to be secondary to lack of familiarity with the condition among clinicians.
• Patients with catatonia are not receiving treatments known to be effective for this condition
(benzodiazepines, ECT (Electroconvulsive Therapy), and discontinuing antipsychotics).
• Agitated forms of catatonia, accompanied by aggression, are a common presentation among a
subgroup of psychiatric patients who are at a higher risk for this syndrome.
Limitations
• Retrospective study design
• Variable data quality because of reliance on computer-assisted methodology.
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Objective: Identify the frequency of catatonia among at-risk children
and adolescents receiving psychiatric treatment.
Method: Subjects were children and adolescents (<18 years), who had
received psychiatric treatment at a University Hospital during 2004–
2009, and were diagnosed with disorders with known risk for catatonia
or displayed symptoms suggestive of catatonia. Approval was obtained
from the Investigational Review Board (IRB). The ﬁrst 101 (n = 101)
subjects were selected among 570 subjects identiﬁed by psychiatric
diagnoses: any pervasive developmental disorder, psychosis-NOS (Not
Otherwise Speciﬁed), intermittent explosive disorder, mental
retardation, catatonia and neuroleptic malignant syndrome. Subjects
met study-deﬁned criteria for catatonia, if they had three or more of
the following symptoms: unexplained agitation ⁄ excitement, disturbed
or unusual movements, reduced movements, repetitive or stereotyped
movements, or reduced or loss of speech.
Results: Eighteen (17.8%) subjects, among a group suspected to be at
a higher risk for catatonia, met the study-deﬁned criteria for this
syndrome. However, only two subjects had been diagnosed by their
treatment providers. Higher rates of intellectual disability and
aggression were found among the group that met study-criteria.
Conclusion: We concluded that catatonia is under recognized and
undertreated among children and adolescents receiving psychiatric
treatment.
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speech (perseveration or senseless repetition of
words or phrases, mimicking the speech of others,
loss of ability touse sign language amongnon-verbal
patients, or mutism among severe cases), reduced
functioning (loss of skills such as toileting, ability to
feed or dress), negativism (often senseless refusal to
comply), and reduced food or ﬂuid intake (may
result in dangerous, medically compromised states).
Symptomsmaybepresent indiﬀerent combinations,
depending on illness-severity and premorbid func-
tioning of the individual. The condition may persist
for years, if not recognized and treated with eﬀective
treatments (1). In some severe cases, the condition
may be accompanied by physical symptoms (car-
diovascular in neuroleptic malignant syndrome;
gastro-intestinal in serotonin syndrome) that are
regarded by some as diverse manifestations of
the same syndrome (2). It should be noted that the
current classiﬁcation system for psychiatric disor-
ders, used in DSM-IV (diagnostic and statistical
manual of mental disorders), only permits catatonia
associated with medical conditions, or aﬀective
disorders and schizophrenia. Many experts in the
ﬁeld argue that catatonia shouldbe acknowledgedas
a broad code in DSM5, and a non-coded catatonia
speciﬁer (proposed in revisions) will badly serve
clinical practice and research (3, 4).
On a historical note, catatonia was originally
described in 1874 by Kahlbaum (5) as a separate
brain disorder with a cyclic, alternating, and a
progressive course. Kahlbaum described the con-
dition among a group of (n = 26) adult patients,
ranging in age from 20 to 44 years. It was
incorporated as a type of dementia praecox or
schizophrenia by Kraepelin in 1896 (6). Since the
1970s, various authors have described catatonia to
be a feature in aﬀective disorders in adults,
particularly mania (7–12).
Systematic studies of catatonia ﬁnd that it is a
relatively common condition among psychiatric
patients; one cross-cultural study found rates
ranging between 10% and 13% (13). Others have
found that certain diagnostic groups may be at a
relatively higher risk such as autism ⁄pervasive
developmental disorders (PDD) (14), mental retar-
dation and other developmental disabilities (14),
aﬀective disorders (15, 16), and schizophrenia (17,
18). Among a long list of associated medical
conditions are some speciﬁc conditions as enceph-
alitis (19), meningitis (20), secondary to antipsy-
chotic medications (21), toxins and infections
(22–24). However, a high rate of 17% is noteworthy
among patients with autism spectrum disor-
der ⁄PDD (14, 25). Further, it has been suggested
that there appear to be several areas of overlap
between autism and catatonia (26).
Aims of the study
The present study was undertaken to identify the
frequency of catatonia among children and ado-
lescents at a mid-western university hospital, based
on a retrospective chart review. Subjects were
patients who had received psychiatric treatment,
either during hospitalization or in outpatient
clinics, were under the age of 18 years, were at an
elevated risk for catatonia because they belonged
to a risk group diagnosed with autism (alone or
with mental retardation), were diagnosed with a
disorder with a likely symptom overlap with
catatonia (psychosis-NOS (Not Otherwise Speci-
ﬁed), intermittent explosive disorder, mental retar-
dation), and ⁄or were already diagnosed with
catatonia or neuroleptic malignant syndrome.
Material and methods
Data were initially collected for a quality improve-
ment project and to increase awareness regarding
catatonia among clinicians. Five hundred and
seventy (n = 570) patients, under the age of
18 years, were identiﬁed from a University billing
data base who had received psychiatric treatment
between 2004 and 2009. Patients were selected if
they had been diagnosed with any of the following
psychiatric disorders: any pervasive developmental
disorder (autistic disorder, PDD-NOS, Asperger
syndrome), psychosis-NOS, intermittent explosive
disorder, mental retardation, catatonia, or neuro-
leptic malignant syndrome (NMS). Investigational
Review Board (IRB) approval was obtained for the
publication of these data.
Next, among the subjects identiﬁed, hospital
electronic medical records were searched, using
EMERSE (Electronic Medical Record Search
Engine), which is an electronic data search program
and is used to identify symptoms of interest
(whether present or absent) using key search terms
(27). The key search terms used were as follows:
aggression, unexplained excitement ⁄agitation, dis-
turbed or unusual movements, reduced movements,
stereotyped or repetitive movements and behaviors,
reduced or loss of speech, reduced appetite and
reduced food or ﬂuid intake. Each key term was
entered in a variety of ways to identify all related
symptoms, while diagnostic labels stated above
were not re-entered at this point.
Further detailed data were collected for the ﬁrst
101 subjects among this subgroup. These addi-
tional data could be only collected for a subgroup
because of resource limitations. Data were demo-
graphic information, psychiatric and medical diag-
noses, symptom details (symptom present ⁄absent,
Ghaziuddin et al.
34
severity and duration of symptom), psychotropic
medications received, laboratory tests and outcome
(if available).
Finally, the frequency of catatonia diagnosed by
investigators was compared with the frequency by
treating psychiatrists. For the purpose of this
study, catatonia was deﬁned as the presence of
three or more of the following symptoms: unex-
plained excitement ⁄agitation, unusual movements,
reduced movements, repetitive or stereotyped
movements, and reduced or loss of speech.
Results
The overall group of 101 subjects was predomi-
nantly male = 80.2%, current age = 13.9 ± 2.04
years, age of ﬁrst psychiatric contact in years =
6.3 ± 3.4 (range = 1–14); pervasive developmen-
tal disorder ⁄autism spectrum disorder diagno-
sis = 81%; the frequency of key symptoms in the
overall group was excitement ⁄agitation pres-
ent = 75.2%, disturbed ⁄unusual movements =
33%, reduced speech = 29%; and reduced mobil-
ity ⁄movement = 15%. Reduced appetite ⁄ reduced
food intake was found in = 32% and reduced
ﬂuid intake in = 13%. Creatinine phosphokinase
enzyme (CPK) was checked in 5%, but was
recorded in medical documentation for only two
subjects (level = 339 and 677 IU ⁄ l, respectively),
and benzodiazepines were administered to 29%.
Using our stringently deﬁned criteria for catato-
nia (presence of three or more symptoms), 17.8%
subjects met investigator-based criteria for catato-
nia. Catatonia was diagnosed in only two subjects
by the treatment providers. A variety of diagnoses
had been given (to these two subjects), including a
mood disorder, psychotic disorder NOS, and
impulse control disorder. Both subjects were addi-
tionally diagnosed with PDD. Despite the identi-
ﬁcation of catatonia, only one of the two subjects
was treated with benzodiazepines. Neither sub-
ject was treated with ECT (Electroconvulsive
Therapy).
The 18 subjects identiﬁed with catatonia by the
investigators diﬀered signiﬁcantly from the rest of
the group in being older at the time of data
collection (15.2 ± 1.5 vs. 13.7 ± 2; df = 99, P =
0.003) and had a lower score of global functioning
(GAF = 38 vs. 48; df = 84, P = 0.04; the last
recorded GAF score). Marked diagnostic diﬀer-
ences (diagnoses were made at any time during
treatment) included a lower rate for bipolar disor-
der diagnosis: 1 (5.6) vs. 27 (32.5); lower rate for
disruptive behavior disorder: 3 (16.7) vs. 44 (53).
However, mental retardation was more common
among this group: 9 (50) vs. 12 (14.5). Other
signiﬁcant diﬀerences were a greater likelihood of
receiving antipsychotics during the past 5 years
(18 ⁄18 vs. 45 ⁄83; P = 0.00), greater likelihood of
receiving a benzodiazepine (10 ⁄18 vs. 19 ⁄83;
P = 0.005) (treatment given at any time during
service), and a higher likelihood of positive seizure
activity was identiﬁed on EEG (Electro-Encepha-
logram) (2 ⁄18 vs. 3 ⁄83; P = 0.002).
Aggression was more common among the group
diagnosed with catatonia compared with the non-
catatonic group (v2 = 9.8, df = 2, P = 0.008).
Similarly, reduced movements (v2 = 14.7, df = 1,
P = 0.00) and loss of speech (v2 = 38.3, df = 1,
P = 0.00) were also more common among this
group. Despite the greater frequency of aggression
and agitation ⁄ excitement, the severity of both
symptoms did not diﬀerentiate the groups.
Figure 1 describes the frequency of symptoms
among groups with and without catatonia. Table 1
describes diagnoses, laboratory ﬁndings, symp-
toms, and treatment-related issues among the
entire group and between-group diﬀerences (those
who met or did not meet criteria).
Discussion
In summary, our ﬁndings are: i) We identiﬁed a
high rate of catatonia (17.8%) using a relatively
stringent criterion (presence of three or more
symptoms) among a group of children and ado-
lescent clustered by their diagnoses (PDD, mental
retardation, psychosis-NOS, and intermittent
explosive disorders, catatonia, NMS); ii) Although
catatonia was used as a key search term, only two
cases had been diagnosed with catatonia by their
treatment providers; clearly, the diagnosis is rarely
given or treated using established treatments; iii)
Fig. 1. Symptom-frequency suggestive for catatonia among
groups I and II.
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Aggression was a common symptom among
subjects who met the study-deﬁned criteria for
catatonia; however, the severity of aggression did
not diﬀerentiate the groups; iv) Data pertaining to
repetitive or stereotyped movements were rarely
documented by treatment providers; v) Psychomo-
tor retardation was less prominent than agita-
tion ⁄ excitement among subjects identiﬁed with
catatonia, suggesting that despite the presence of
both retardation and agitation ⁄ excitement, the
latter symptoms may be the hallmark symptom;
vi) Previously known associations, such as male
preponderance and association with antipsychot-
ics, were supported by our ﬁndings; vii) Only one
subject among the entire group of 101 subjects was
diagnosed with schizophrenia; this subject did not
meet the study-deﬁned criteria for catatonia,
thereby lending further support that catatonia is
possibly more common among diagnoses other
than schizophrenia.
Clinical implications of this study are that cata-
tonia is frequently missed, suggesting that many
psychiatrists are possibly unfamiliar with this con-
dition that benzodiazepines are infrequently pre-
scribed and CPK levels and EEG recording are
rarely completed. The subgroup with catatonia was
found to have poor overall functioning, indicated by
a low score of global functioning (last recorded
score). Lower symptom-severity scores involving
loss of speech ⁄ reduced speech and reduced move-
ments, while a higher frequency of aggression and
agitation ⁄ excitement, suggest that an agitated form
of the disorder, rather than a classical retarded
formof catatonia,may bemore commonamong this
patient group. Further, based on the symptom
presentation of this group, this population undoubt-
edly places enormous burden of care on care-givers
and providers alike.
The main strength of this study is that we used
stringently deﬁned criteria for catatonia (the pres-
ence of three or more symptoms), while DSM-IV
requires the presence of only two symptoms for
identifying catatonia. Therefore, it is possible that
a higher prevalence than 17.8% may be found if
DSM-IV criteria were applied.
Study limitations are retrospective design and
variable quality of data obtained by computer-
assisted chart review. For example, it was not
possible to conclude whether the symptoms identi-
ﬁed were simultaneously present, determine
symptom duration or the exact timing when an
antipsychoticor abenzodiazepinewasadministered.
Our ﬁndings suggest that catatonia is not a rare
condition among child and adolescent psychiatric
patients. This observation is similar to what is
noted among adult patients that the condition is
underdiagnosed and undertreated. During the
early 1980s, catatonia was thought to be almost
extinct. However, recent studies ﬁnd that preva-
lence rates may range from 7% to 17% among
adult psychiatric patients with aﬀective or psy-
chotic disorders, who are hospitalized to acute
facilities (13, 28), suggesting that catatonia is
underdiagnosed (29, 30). Under diagnosis of cat-
atonia may be due to the historical decision to
classify catatonia as a type of schizophrenia, the
segregation in long-term facilities of severely ill
psychiatric patients and patients with developmen-
tal disorders, the perceived lack of anti-catatonic
treatments, and the disparagement of physical and
neurological examination by psychiatrists (28).
Our study shows that there is a failure to
recognize catatonia or treat with eﬀective treat-
ments (lorazepam and ECT) children and adoles-
cents who are receiving psychiatric care. These
ﬁndings, among other published data, call for an






n = 83 (82%)
Group 2 (3 or
4 symptoms),




Any depression present 14 (13.9) 12 (14.5) 2 (11) ns
Any bipolar disorder present 28 (27.7) 27 (32.5) 1 (5.6) 0.02*
Any anxiety disorder present 19 (18.8) 15 (18.1) 4 (22.2) ns
Any disruptive behavior disorder present 47 (46.5) 44 (53) 3 (16.7) 0.005*
Any pervasive developmental disorders present 81 (80.2) 65 (78.3) 16 (89) ns
Mental retardation 21 (20.8) 12 (14.5) 9 (50) 0.002
Aggression 71 (70.3) 55 (66.3) 16 (88.9) 0.02*
Benzodiazepine received 29 (28.7) 19 ⁄ 83 (22.9) 10 ⁄ 18 (55.6) 0.005*
Antipsychotics received during past 5 years 63 (62.4) 45 ⁄ 83 (55) 18 ⁄ 18 (100) 0.00*
ECT received 2 (2.0) 1 ⁄ 83 (1.2) 1 ⁄ 18 (5.6) ns
Creatinine phosphokinase enzyme measured 5 (5) 3 ⁄ 83 (3.6) 2 ⁄ 18 (11.1) ns
EEG completed 15 (14.9) 7 ⁄ 83 (8.4) 8 ⁄ 18 (44.4) 0.00*
Seizure activity in EEG 4 (4) 2 ⁄ 83 (2.4) 2 ⁄ 18 (11.1) 0.002*
*Variable differentiates between those with three or more symptoms suggestive of catatonia vs. those with <3 symptoms.
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urgent need to identify symptoms of catatonia
during psychiatric history-taking and examination
that psychiatrist must acquire the skills necessary
to elicit physical symptoms of catatonia and
become familiar with standardized rating scales
that are important in diagnosis and measuring
symptom severity. Commonly used ratings scales
are the Bush Francis Catatonia Rating Scale,
Braunig Catatonia Scale, and Northoﬀ Catatonia
Rating Scale, which are helpful in identifying and
for measuring change in symptoms such as rigidity,
grasp reﬂex, mitgehen, gegenhalten, and reduced
inhibitory control (31, 32).
Other broader remedial actions may include
separating catatonia from psychosis and schizo-
phrenia in psychiatric classiﬁcation, thereby
improving early diagnosis and treatment of cata-
tonia in children and adolescents, especially those
with autistic or other developmental disorders (4).
The occurrence of catatonia in adolescents with a
non-psychotic disorder like autism is an important
ﬁnding that further loosens the historical link
between catatonia and psychosis ⁄ schizophrenia.
Frequent presence of aggression among subjects
diagnosed with catatonia also calls attention to
considering catatonia in the diﬀerential diagnoses
among patients with aggression.
ECT is likely to remain an essential component
in the treatment of catatonia. Wider recognition of
the beneﬁts of ECT in pediatric patients with
catatonia will help reduce stigma of ECT when
recommended for children and adolescents or
patients with developmental disorders. To a lesser
extent, this would also apply to the use of
benzodiazepines, which are frowned upon when
prescribed in high doses, but often critical for
successful treatment. Treatment trials of catatonia
are warranted in children and adolescents with
aﬀective, psychotic, autistic, developmental, and
medical conditions.
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